Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy

Kalhan, Atul, Gharibi, Borzo, Vazquez, Marisol, Jasani, Bharat, Neal, James William, Kidd, M., Modlin, I. M., Pfragner, R., Rees, Dafydd Aled ORCID: https://orcid.org/0000-0002-1165-9092 and Ham, Jack 2012. Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy. Purinergic Signalling 8 (2) , pp. 265-274. 10.1007/s11302-011-9280-5

Full text not available from this repository.

Abstract

The clinical management of neuroendocrine tumours is complex. Such tumours are highly vascular suggesting tumour-related angiogenesis. Adenosine, released during cellular stress, damage and hypoxia, is a major regulator of angiogenesis. Herein, we describe the expression and function of adenosine receptors (A1, A2A, A2B and A3) in neuroendocrine tumours. Expression of adenosine receptors was investigated in archival human neuroendocrine tumour sections and in two human tumour cell lines, BON-1 (pancreatic) and KRJ-I (intestinal). Their function, with respect to growth and chromogranin A secretion was carried out in vitro. Immunocytochemical data showed that A2A and A2B receptors were strongly expressed in 15/15 and 13/18 archival tumour sections. Staining for A1 (4/18) and A3 (6/18) receptors was either very weak or absent. In vitro data showed that adenosine stimulated a three- to fourfold increase in cAMP levels in BON-1 and KRJ-1 cells. The non-selective adenosine receptor agonist (adenosine-5′N-ethylcarboxamide, NECA) and the A2AR agonist (CGS21680) stimulated cell proliferation by up to 20–40% which was attenuated by A2B (PSB603 and MRS1754) and A2A (SCH442416) receptor selective antagonists but not by the A1 receptor antagonist (PSB36). Adenosine and NECA stimulated a twofold increase in chromogranin A secretion in BON-1 cells. Our data suggest that neuroendocrine tumours predominantly express A2A and A2B adenosine receptors; their activation leads to increased proliferation and secretion of chromogranin A. Targeting adenosine signal pathways, specifically inhibition of A2 receptors, may thus be a useful addition to the therapeutic management of neuroendocrine tumours.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	adenosine, A2A adenosine receptor, A2B adenosine receptor, human neuroendocrine tumours, cell proliferation, chromogranin A
Additional Information:	Online first
Publisher:	Springer
ISSN:	1573-9538
Last Modified:	18 Mar 2023 02:06
URI:	https://orca.cardiff.ac.uk/id/eprint/23593

Citation Data

Cited 23 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item